伊朗成人炎症性肠病生物制剂和小分子药物治疗共识指南

Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh
{"title":"伊朗成人炎症性肠病生物制剂和小分子药物治疗共识指南","authors":"Niloofar Khoshnam-Rad,&nbsp;Homayoon Vahedi,&nbsp;Anahita Sadeghi,&nbsp;Mansoor Rastegarpanah,&nbsp;Soha Namazi,&nbsp;Amir Anushiravani,&nbsp;Ali Reza Sima,&nbsp;Shabnam Shahrokh,&nbsp;Sudabeh Alatab,&nbsp;Reza Malekzadeh","doi":"10.34172/mejdd.2023.327","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Pharmacotherapy with biologics and small molecules, as the more effective therapies for moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), is complex. Choosing the best methods for their utilization in order to induce and maintain remission are critical for practicing gastroenterologists. We aimed to develop an Iranian consensus on the management of inflammatory bowel disease (IBD) patients with biologics and small molecules. <b>Methods:</b> A Delphi consensus was undertaken by experts who performed a literature summary and voting process. Quality of evidence was assessed using the Grading and Recommendations Assessment, Development, and Evaluation; and an additional risk of bias-protocol. <b>Results:</b> Following an extensive search of the literature, 219 studies were used to determine the quality of the evidence. After three rounds of voting, consensus (defined as≥80% agreement) was reached for 87 statements. <b>Conclusion:</b> We considered different aspects of pharmacotherapy in this consensus. This guideline, along with clinical judgment, can be used to optimize management of IBD patients.</p>","PeriodicalId":18517,"journal":{"name":"Middle East Journal of Digestive Diseases","volume":"15 2","pages":"83-106"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/d2/mejdd-15-83.PMC10404092.pdf","citationCount":"0","resultStr":"{\"title\":\"Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases.\",\"authors\":\"Niloofar Khoshnam-Rad,&nbsp;Homayoon Vahedi,&nbsp;Anahita Sadeghi,&nbsp;Mansoor Rastegarpanah,&nbsp;Soha Namazi,&nbsp;Amir Anushiravani,&nbsp;Ali Reza Sima,&nbsp;Shabnam Shahrokh,&nbsp;Sudabeh Alatab,&nbsp;Reza Malekzadeh\",\"doi\":\"10.34172/mejdd.2023.327\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Pharmacotherapy with biologics and small molecules, as the more effective therapies for moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), is complex. Choosing the best methods for their utilization in order to induce and maintain remission are critical for practicing gastroenterologists. We aimed to develop an Iranian consensus on the management of inflammatory bowel disease (IBD) patients with biologics and small molecules. <b>Methods:</b> A Delphi consensus was undertaken by experts who performed a literature summary and voting process. Quality of evidence was assessed using the Grading and Recommendations Assessment, Development, and Evaluation; and an additional risk of bias-protocol. <b>Results:</b> Following an extensive search of the literature, 219 studies were used to determine the quality of the evidence. After three rounds of voting, consensus (defined as≥80% agreement) was reached for 87 statements. <b>Conclusion:</b> We considered different aspects of pharmacotherapy in this consensus. This guideline, along with clinical judgment, can be used to optimize management of IBD patients.</p>\",\"PeriodicalId\":18517,\"journal\":{\"name\":\"Middle East Journal of Digestive Diseases\",\"volume\":\"15 2\",\"pages\":\"83-106\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/d2/mejdd-15-83.PMC10404092.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Middle East Journal of Digestive Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/mejdd.2023.327\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Digestive Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/mejdd.2023.327","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:生物制剂和小分子药物治疗作为中重度溃疡性结肠炎(UC)和克罗恩病(CD)更有效的治疗方法是复杂的。为了诱导和维持缓解,选择最佳的方法对胃肠病学家来说是至关重要的。我们的目标是在使用生物制剂和小分子治疗炎症性肠病(IBD)患者方面达成伊朗共识。方法:由专家进行文献总结和投票过程进行德尔菲共识。使用分级和建议评估、开发和评估来评估证据的质量;还有额外的偏见风险。结果:经过广泛的文献检索,219项研究被用于确定证据的质量。经过三轮投票,87项意见达成共识(定义为同意度≥80%)。结论:我们在这个共识中考虑了药物治疗的不同方面。该指南与临床判断可用于优化IBD患者的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases.

Background: Pharmacotherapy with biologics and small molecules, as the more effective therapies for moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), is complex. Choosing the best methods for their utilization in order to induce and maintain remission are critical for practicing gastroenterologists. We aimed to develop an Iranian consensus on the management of inflammatory bowel disease (IBD) patients with biologics and small molecules. Methods: A Delphi consensus was undertaken by experts who performed a literature summary and voting process. Quality of evidence was assessed using the Grading and Recommendations Assessment, Development, and Evaluation; and an additional risk of bias-protocol. Results: Following an extensive search of the literature, 219 studies were used to determine the quality of the evidence. After three rounds of voting, consensus (defined as≥80% agreement) was reached for 87 statements. Conclusion: We considered different aspects of pharmacotherapy in this consensus. This guideline, along with clinical judgment, can be used to optimize management of IBD patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Middle East Journal of Digestive Diseases
Middle East Journal of Digestive Diseases Medicine-Gastroenterology
CiteScore
1.20
自引率
0.00%
发文量
33
审稿时长
12 weeks
期刊最新文献
Altered Cytokine Production in Patients with Helicobacter pylori Infection. Celiac Crisis: A Life-Threatening Complication of Celiac Disease. Correlation between Autoimmune Hashimoto's Thyroiditis and Helicobacter pylori Infection: A Case-Control Study. Developing Mobile Health Applications for Inflammatory Bowel Disease: A Systematic Review of Features and Technologies. Ulcerative and Cytomegalovirus Colitis Associated with Fournier's Gangrene: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1